265 results
8-K
EX-99.1
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
relating to the prior failure to fund by certain investors in the private placement. We are pursuing litigation against the other two larger investors who … contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words
8-K
EX-99.1
KA
Kineta Inc
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as, but not limited to, “believe
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
Regarding Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation
8-K
lkxip5r d3
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
7tirl 3v2
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.2
5wfsu2b4ockwutp23z2
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
z33e8e43n7tox
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-10.1
kir r326e1fb86
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-10.2
gffzur
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-99.1
mp2ghxr2s
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-99.1
aiq4n5gsalft6z970uv
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
EX-99.1
za5ekb
5 Jan 24
Regulation FD Disclosure
4:30pm
424B3
ju5b9ee 3cr98v
13 Nov 23
Prospectus supplement
5:28pm
8-K
EX-99.2
3gibm2h4
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
htjgrgq1xup qs
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
q9bwzvshdgzx99aj
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm